Breaking News

SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax

Will leverage SUREtechnology Platform to generate stable, high-yield production cell lines needed for human clinical trials.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV). SpyBiotech will leverage Selexis’ SUREtechnology Platform to generate the stable, high-yield production cell lines needed to advance the HCMV program to human clinical trials. “SpyBiotech’s SpyTag/SpyCatcher technology circumvents the significant compl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters